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Abstract The coincidental increase in norovirus outbreaks
and Clostridium difficile infection (CDI) raised the question
of whether these events could be related, e.g. by enhancing
spread by diarrhoeal disease outbreaks. Therefore, we
studied the prevalence of C. difficile in outbreaks of viral
gastroenteritis in nursing homes for the elderly and charac-
terised enzyme immunoassay (EIA)-positive stool samples.
Stool samples from nursing home residents (n=752) in 137
outbreaks of viral aetiology were investigated by EIA for the
presence of C. difficile toxins. Positive samples were further
tested by a cell neutralisation cytotoxicity test, a second EIA
and culture. Cultured isolates were tested for the presence of
toxin genes, the production of toxins and characterised by
16S rRNA polymerase chain reaction (PCR) and sequencing.
Twenty-four samples (3.2%) tested positive in the EIA. Of
these 24 positive samples, only two were positive by
cytotoxicity and three by a second EIA. Bacterial culture of
21 available stool samples yielded a toxinogenic C. difficile
PCR ribotype 001 in one patient sample only. In conclusion,
we found no evidence in this retrospective study for an
association between viral gastroenteritis outbreaks and
C. difficile. The high rate of false-positive EIA samples
emphasises the need for second confirmation tests to
diagnose CDI.
Introduction
Outbreaks of acute gastroenteritis (AGE) of suspected viral
aetiology are reported to the National Institute for Public
Health and the Environment (RIVM) as part of the ongoing
viral gastroenteritis outbreak surveillance system. Although
these outbreaks are selected based on criteria thought to be
highly specific for viral gastroenteritis outbreaks, and
despite extensive testing, the cause of approximately 12%
of outbreaks of AGE remains unknown [1]. Of the
outbreaks in which a viral pathogen was detected, the vast
majority is associated with noroviruses (NoV).
Since 2002, the epidemiology of NoV appears to have
changed, with the introduction of a novel lineage of the
dominant genogroup (G) II.4 viruses. This introduction
coincided with increased levels of reporting of NoV
outbreaks across Europe and a noticeable peak in mortality
in the elderly, which coincides with the NoV seasonal peak
[2]. Simultaneously, Canada, the USA and, later, the United
Kingdom (UK), the Netherlands, Belgium, France and
Austria reported the emergence of Clostridium difficile
ribotype 027, which appeared to have increased virulence
compared to other C. difficile strains [3, 4]. In the
Netherlands, this ribotype was detected in 26 hospitals
and ten nursing homes by May 2008 [5, 6]. Antibiotic use
has been associated with an increased risk of infection with
C. difficile and is responsible for 15 to 25% of all cases of
antibiotic-associated diarrhoea in hospitals [7]. Outbreaks
and cases outside hospitals are less frequently recognised
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but have been described, sometimes without the typical risk
factors [8, 9]. C. difficile outbreaks and cases in nursing
homes have been studied less systematically and, although
C. difficile type 027 has been found in at least ten nursing
homes in the Netherlands, detailed information about these
infections is absent [6].
The coincidental increase in norovirus GII.4 outbreaks
and the spread of C. difficile ribotype 027 raised the
question of whether these events could be related [2, 10]. In
theory, mixed infections of NoV and C. difficile ribotype
027 could increase the severity of the disease. Furthermore,
norovirus-induced episodes of vomiting and diarrhoea
might trigger or exacerbate C. difficile diarrhoea, resulting
in increased spread of C. difficile due to multiple episodes
of vomiting and diarrhoea, as has been suggested in some
recent publications [11–13]. Therefore, we decided to
investigate a possible association of norovirus and rotavirus
outbreaks with C. difficile infections (CDIs), particularly
with respect to C. difficile polymerase chain reaction (PCR)
ribotype 027.
Materials and methods
Sample collection
In total, we tested 752 faecal samples from 137 outbreaks of
gastroenteritis (number of stool samples varying from 2 to 25
per outbreak). All outbreaks occurred in 2006 in nursing
homes and were selected because the C. difficile ribotype 027
problem emerged in that period in the Netherlands and these
samples provided a snapshot of what is present within the
elderly population. Viral detection has been performed as
described previously by Svraka et al. [1]. The outbreaks were
first tested using the assays for NoV. Then, all outbreaks that
remained negative were further tested using the assays for
rotaviruses, adenoviruses, astroviruses and sapoviruses [1].
Of these, 109 were confirmed norovirus outbreaks (644 stool
samples), 14 outbreaks were confirmed rotavirus outbreaks
(70 samples) and 14 outbreaks (38 samples) were of
unexplained aetiology, reflecting the typical aetiology of
such outbreaks. The outbreaks were reported throughout the
year, but with a peak in winter, as part of our ongoing
surveillance for viral gastroenteritis outbreaks, which
explains the high number of NoV outbreaks in this study
[1]. Undiluted stool samples had been stored at 4°C, as
recommended for viral gastroenteritis diarrhoea, before
testing for the presence of C. difficile.
Diagnostic assays used for the screening of samples
The screening of 752 outbreak specimens for the presence of
C. difficile was done using the PTAB enzyme immunoassay
(EIA, Premier C. difficile Toxin A&B, Meridian Diagnostics,
Inc., Cincinnati, OH, USA) on all stool samples. Assay was
performed as described by the manufacturer. The stool
samples had been stored at 4°C for periods longer than 3–
4 days, which is in accordance with recommendations for the
diagnostics of viral gastroenteritis, but not in accordance to
the manufacturer’s recommendations, before testing for the
presence of C. difficile. Consequently, we validated the
PTAB EIA assay for use in samples that were stored longer
at 4°C by the parallel testing of 96 stool samples that were
aliquoted directly after receipt and stored for five months at
−20 and 4°C.
The PTAB EIA was interpreted visually (within 15 min)
and by spectrophotometer (within 30 min), as described by
the manufacturer; 376 samples were read both visually and
on a Labsystems Multiskan RC spectrophotometer plate
reader (Thermo Fisher Scientific, Breda, the Netherlands)
using dual wavelengths of 450 and 450/630 nm. The
samples were described as positive if optical density (OD)
values of 0.100 or more were measured at a wavelength of
450/630 nm and/or 0.150 or more at a wavelength of
450 nm, as described by the manufacturer. There was 100%
concordance between reading visually and by using the
spectrophotometer plate reader. The remaining 376 samples
were read visually only.
Confirmatory testing on PTAB-positive samples
Stool samples found positive using the PTAB EIA assay were
cultured and tested using a neutralisation cytotoxicity assay
and the automated immunoanalyzer VIDAS®C. difficile A &
B (bioMérieux) [14].
For culture, stool samples found positive in the PTAB
EIA assay were treated with absolute ethanol (96%) prior to
inoculation onto Columbia agar containing colistin and
nalidixic acid, C. difficile-selective agar with cefoxitin,
amphotericin B and cycloserine (CLO; bioMérieux) and
blood agar. CLO medium was also used to inoculate faecal
samples without pre-treatment with ethanol. Inoculated
faecal samples were incubated in an anaerobic environment
at 37°C for 2 days.
Clostridium-suspected colonies were tested further using
PCR assays for C. difficile-specific GluD targeting the
GDH gene [15], C. difficile ribotyping [16, 17], enterotoxin
A (tcdA) [5], cytotoxin B (tcdB) [18] and 16S rRNA PCR
[19]. For this, DNA was isolated from suspected colonies
by a QIAamp DNA isolation column (Qiagen, Holden,
Germany) according to the manufacturer’s recommendations,
including 10 min incubation at 55°C with proteinase K. The
final volume of the DNA extracts was 200 µL.
The neutralisation cytotoxicity assay was performed
using Vero cells in a 24-well format. Faecal samples were
diluted in 1:4 Eagle’s minimum essential medium (EMEM)
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containing 5% foetal bovine serum and centrifuged for
10 min at 3,000 rpm. The supernatant was filtered through a
0.45-µm-pore filter, 150 µL supernatant was mixed with
150 µl EMEM and neutralisation of the cytotoxic effect
was performed using 150 µL faecal supernatant and 150 µl
of 1:25 dilution of specific C. difficile antitoxin (Techlab,
Blacksburg, VA, USA). These two mixtures were incubated
for 30 min at room temperature; subsequently, 200 µl of
each mix was inoculated on Vero cells. The cytotoxic effect
was evaluated daily for 3 days microscopically.
Stool samples positive in the PTAB EIA were also tested
using the VIDAS assay. Stool samples were centrifuged for
10 min at maximum speed (14,000 rpm) and 300 µl of
supernatant was used, according to the manufacturer’s
instructions. Samples with OD value lower than 0.13 were
described as negative, OD values between 0.13 and 0.37 were
equivocal and OD values higher than 0.37 were described as
positive.
Bacterial isolates cultured from EIA-positive faeces
samples were also investigated for the production of tcdA
and tcdB by VIDAS and EIA. Bacteria were cultured in
liquid brain heart infusion (BHI) bouillon medium for 4
days. Subsequently, the BHI cultures were centrifuged at
3,000 rpm for 10 min and the supernatant was further
investigated. The same cut-off values of EIA and VIDAS
were used for in vitro bacterial toxin production as for toxin
detection in faeces samples.
Evaluation of the approach of Clostridium detection
Optimal sample storage conditions differ for viral testing
and bacterial testing, and this raised the question whether
Clostridium EIA test results could be explained by
suboptimal use of the assay. Therefore, we validated this
approach by testing original total nucleic acids isolated
from 154 (20% of all samples tested in the EIA) faecal
samples within 3 days of arrival from the stool samples
which were included in our study. These extracts had been
stored at −80°C. We used a real-time PCR for the tcdB
gene, as described by van den Berg et al. [14, 20]
Results
Testing of stool samples using the PTAB EIA
For the validation of the use of the PTAB EIA on our sample
set, we used 96 stool samples that were stored for 5 months at
−20 and at 4°C. Of the samples stored at −20°C, two were
positive, and of the samples stored at 4°C, three were positive,
including the ones that were positive after storage at −20°C.
In total, 24 (3.2%) of 752 stool samples from outbreaks
of acute gastroenteritis in nursing homes in 2006 tested
positive in the PTAB EIA assay (Table 1). Of the 24 PTAB
EIA-positive stool samples, 22 were from 17 norovirus
outbreaks, one was from a rotavirus outbreak and the other
one was from an outbreak of unexplained aetiology.
Confirmatory testing of PTAB-positive stool samples
Specialised stool culture for Clostridium spp. (Table 1) was
performed on 24 stool samples. For three stool samples,
culture was negative, and in 21 stool samples, Clostridium-
suspected colonies were found. Subsequently, neutralisation
cytotoxicity assay and VIDAS assay were performed on 21
stool specimens of which sufficient amounts of material were
available. This yielded two positive samples both by
neutralisation cytotoxicity assay and VIDAS, and an addi-
tional weakly positive result using the VIDAS assay (Table 1).
Analysis of bacterial isolates from the stool samples
From the 21 Clostridium-suspected colonies, which were
grown on the CLO medium plates, DNA was extracted and
analysed by 16S DNA sequencing and further using a
range of assays for the characterisation of toxin-producing
C. difficile (Table 1). 16S DNA sequencing revealed
Lactobacilli in six stool samples (37.5%) and different
Clostridium species in 15 samples (62.5%): C. difficile,
C. disporicum, C. perfringens, C. sordellii, C. boltei,
C. butyricum, C. baratii, C. subterminale and C. bifermen-
tans (Table 1). Using the GluD, ribotyping PCR, tcdA and
tcdB assays, one sample was positive and identified as
C. difficile. One isolate of C. disporicum was weakly
positive for tcdA and one isolate of C. subterminale for tcdB.
One Clostridium species from a faecal sample (13/8,
Table 1) tested positive by EIA, cytotoxicity and VIDAS
was identified as C. sordellii. This isolate was negative for
tcdA and tcdB and did not produce a cytotoxin.
The results of the in vitro bacterial toxin production
measured by cytotoxicity, PTAB and VIDAS revealed only
strongly positive results for one sample that was identified as
C. difficile. Using cut-off values of PTAB and VIDAS as
applied on stool samples, (weakly) positive reactions were
obtained for 14 samples using PTAB and six samples using
the VIDAS assay. However, none of these isolates produced
cytotoxins.
Epidemiological data on C. difficile- and C. sordellii-positive
samples
Only one stool sample and the corresponding bacterial isolate
were positive in all assays and proven to be C. difficile type
001 (23/18, Table 1). This sample was from an outbreak of
unexplained aetiology that occurred in November 2006, with
eight cases being reported. All eight samples were tested
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using the PTAB EIA; however, only one was positive and
tested further in other assays.
The C. sordellii-positive stool sample (13/8, Table 1) was
from a norovirus outbreak that affected four persons from a
residential institution in an endemic region for C. difficile in
November 2006. The faeces samples of the three other
patients were tested for CDI, but were negative.
Evaluation of the approach of Clostridium detection
Of the 154 total nucleic acids that had been isolated from stool
samples within 3 days of their arrival, the two samples that
were cytotoxic and VIDAS-positive were positive by tcdB
real-time PCR assay (Table 1 samples 13/8 and 23/18). All
other samples were negative.
Discussion
In this study, we investigated whether the emergence of a
successful norovirus strain [10] could coincide with the
spread of C. difficile and whether the emergence of
C. difficile could explain some unresolved outbreaks of acute
gastroenteritis in nursing homes, as has been postulated. This
was initiated by publications suggesting that such an
association may exist [11–13, 21]. We did not find any
evidence for such an association in our retrospective study.
C. difficile PCR ribotype 001 was found in a single patient in
one gastroenteritis outbreak of unexplained aetiology in a
nursing home. This type is one of the most frequently
circulating and detected types in the Netherlands.
However, our study was performed on outbreaks in
nursing homes, while other studies describe hospital
outbreaks, where CDIs are more common [3–5]. Wilcox
and Fawley have shown that CDI rates are higher in closed
hospital units which are affected by viral gastroenteritis
than in open units where no viral gastroenteritis was
detected [11]. Their results were not confirmed using C.
difficile-specific assays, and our data suggest that false-
positivity may explain previously noted associations between
norovirus and Clostridium. We were unable to confirm the
presence of C. difficile in all but one PTAB EIA-positive
stool. This is not explained by their inability to culture,
because other Clostridium species were isolated from 63.3%
of all reactive samples.
Our study does have some limitations: first, stool
samples had been sent by regular mail and stored at 4°C
with a maximum of 16 months. This is in accordance with
recommendations for the diagnostics of viral gastroenteritis,
but is unusual for CDI tests. We did, however, find that the
sensitivity of the PTAB EIA was not affected by storage of
5 months at 4°C relative to storage at −20°C. Furthermore,
the testing of original total nucleic acids isolated from
faecal samples within 3 days of arrival yielded the same
positives as the combination of cytotoxicity test and
VIDAS. Therefore, we conclude that our findings are not
due to the degradation of C. difficile toxins [22, 23].
In addition, this was a retrospective study and stool
samples were selected from patients with a suspected viral
gastroenteritis [24]. Criteria for viral gastroenteritis differ
from those for Clostridium gastroenteritis, since symptoms
for CDIs are highly variable, ranging from mild diarrhoea to
life-threatening colitis, and including watery diarrhoea [25].
Bignardi et al. noted that, if a large number of stool
specimens are submitted for the testing of the prevalence of
C. difficile during norovirus outbreaks, it is likely that the
number of false-positive results will increase [12]. The
Clostridium species found in this study, such as C. dispor-
icum, C. perfringens, C. sordellii, C. boltei, C. butyricum,
C. baratii, C. subterminale and C. bifermentans, are bacteria
that are commonly found in the gut. These bacterial isolates
did react weakly positive, using the cut-off values for the
faecal material, by C. difficile PTAB EIA, confirming the
specificity problem on stool samples stored for a long period
at 4°C [26–31]. The PTAB EIA has a positive predictive
value (PPV) of 87.4% according to the manufacturer’s
assessment when tested according to the manufacturer’s
recommendations. A prospective multicentre study using the
cytotoxicity assay as a gold standard revealed a PPV value of
50.9% and a specificity of 94.3%, indicating that this assay is
not highly specific when used for broader testing [14]. A
recently performed meta-analysis by the European Study
Group on Clostridium difficile (ESGCD) confirmed the PTAB
to have an unacceptably low PPVof 50% at a prevalence rate
of 5% [32].
A possible explanation for the high rate of false-positive
PTAB results could be that suboptimal sample storage
influenced the tests with weakly positive results just near to
the cut-off values. Unfortunately, we were unable to test this
hypothesis by a comparison of OD values of the false-positive
samples with OD values of CDI-confirmed samples. Nonethe-
less, we recommend additional confirmatory testing, preferably
a cell neutralisation cytotoxicity assay, which is the reference
testing method for detection, or a molecular detection test
including typing, specifically when samples are not sent in and
stored according to C. difficile diagnostic criteria.
In summary, we found no evidence for an association
between the spread of norovirus and C. difficile. Previous
reports that suggested this association may be explained by
false-positive PTAB tests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
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